Vyora provides compounded Semaglutide and Tirzepatide, two GLP-1 medications. These are paired with 24/7 coach access, GLP-1 nutrition support, and a supportive community.

Semaglutide is $299 per month, and Tirzepatide is $399 per month. The price includes GLP-1 nutritional guidance, 24/7 coaching, and community access. Your cost remains the same, even as doses change.

No, Vyora does not accept or require insurance. Some members have been able to pay for the fees with their HSA/FSA accounts.

You’ve got two easy options:

• If you already know what you want, just click any “Get Started” link to head straight to our shop and choose your treatment.

• Not sure which product is right for you? Take our free GLP-1 Health Assessment to get a personalized recommendation from one of our licensed providers. Your results will be reviewed, and a custom plan will be created within 24 hours.

On average, patients using Semaglutide or Tirzepatide for 68 weeks without diet or exercise lost 15% (Semaglutide) and 20% (Tirzepatide) of their body weight in clinical studies. Vyora’s added nutrition support has shown quicker results with lower doses.

We offer account credits for approved refunds, which never expire and can be used on any Vyora product or service. If your order isn’t approved by one of our providers, you’ll receive a full refund to your original payment method. See our full refund policy.

Compounded Semaglutide and Tirzepatide are custom made injectable medications that contain the same active ingredient as Semaglutide (Ozempic) and Tirzepatide (Mounjaro) but is produced by a compounding pharmacy instead of a manufacturer. Our compounding pharmacies are all in the USA and LegitScript Certified.

Semaglutide: A GLP-1 receptor agonist designed to regulate blood sugar, control appetite, and support weight loss. It mimics the natural GLP-1 hormone in your body, making it easier to feel full and consume less.

Tirzepatide: A dual-action medication targeting both GLP-1 and GIP (another key hormone in metabolism). This dual effect can lead to enhanced fat loss and better blood sugar control, often making it more effective for weight loss compared to Semaglutide.

Key Difference: Tirzepatide’s dual-action mechanism gives it a slight edge for those looking for faster results or greater metabolic support, while Semaglutide remains a highly effective, trusted option for sustainable weight loss.

Yes, injectable GLP-1 therapies (Semaglutide & Tirzepatide) require a prescription by a licensed provider.

Yes, Vyora specializes in GLP-1 therapies including Semaglutide and Tirzepatide. These medications are carefully prescribed based on your individual health profile and weight loss goals, ensuring a personalized approach to your journey.

Nope! We use a detailed health assessment form reviewed by our licensed providers. In most cases, they can approve or deny your medication within 24 hours—no video call needed. Occasionally, a quick phone call may be required, but never a video visit.

Injections are done with a small insulin syringe one time per week. We will provide you with visual and written instructions once you are approved.

No need to worry! If you miss your injection day you may begin to experience slight hunger symptoms as the days progress until you can take your next injection. If you stop taking it all together, depending on your most recent dose, you will most likely experience a rapid increase in appetite. Typically, the higher the dose the more aggressive your appetite will return.

You can manage your subscription in two places:

• Medications & Treatment Plans: patient.vyorawellness.com

• Billing & Account Info: vyorawellness.com/my-account

If you need any help, feel free to email our team at support@vyorawellness.com.

We’re connected to 25 of the top compounding pharmacies nationwide, giving us broad access to compounded medications across nearly every state.

• The minimum BMI requirement for a patient starting treatment is 25.

• Minimum BMI of 23. If the patient has a BMI of 23, the provider will discuss moving the patient to a maintenance dosage.

• No BMI requirement.